Fact Meets Function

This study examined how methylene blue (hydromethylthionine) is processed in the body when given orally to Alzheimer’s patients versus healthy people. The researchers found that Alzheimer’s patients process the drug differently than expected, which helps explain why previous clinical trials had unexpected results. The drug targets tau protein clumps in the brain that contribute to Alzheimer’s disease and also has other brain benefits.

This Phase 3 clinical trial tested a methylene blue derivative called HMTM in patients with mild cognitive impairment and early Alzheimer’s disease. The compound works by targeting tau protein tangles in the brain, which are a hallmark of Alzheimer’s. The study measured clinical outcomes, brain imaging changes, and blood markers to assess whether the treatment could slow cognitive decline or improve symptoms.